Funding opportunities for Health and Biotech from the EU Research and Innovation program Horizon 2020 Medtec, 04. April 2017, Stuttgart

Transcription

1 Funding opportunities for Health and Biotech from the EU Research and Innovation program Horizon 2020 Medtec, 04. April 2017, Stuttgart Dr. Lydia Kammler

2 Horizon biggest EU Research and Innovation programme ever with nearly 80 billion of funding available over 7 years (2014 to 2020). taking great ideas from the lab to the market. couples research and innovation. has its emphasis on excellent science, industrial leadership and tackling societal challenges. removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. Horizon 2020 is open to everyone Stuttgart, 04. April

3 Horizon 2020: Work Programme To be published in the 2 nd half of 2017 The European Commission will invest almost 30 billion in research and innovation in the next three years under Horizon 2020 over 10,000 grants funded in Horizon 2020 up to now Stuttgart, 04. April

4 Opportunities and characteristics of EU funding EU funding based on subsidy principle Enhance your reputation Compare your achievements on international level Pool and exchange knowlegde and experience Driven by EU politics (Europe 2020 Strategy) Funding of single researchers and research consortia Funding from basic research to close-to-market activities Projects with partners from different disciplines and sectors Collaboration with partners in Europe and beyond Stuttgart, 04. April

5 Horizon 2020: Understanding the EU Universe Stuttgart, 04. April

6 Strategy for a successful participation in Horizon 2020 EU- Commission Local EUofficer National Contact Points Commissioned by the Research Institute/ Company Member States Stuttgart, 04. April

7 Funding possibilites for ideas in life sciences I. Excellent science II. Industrial Leadership III. Societal Challenges European Research Council - ERC Future & emerging Technologies - FET Marie-Skłodowska-Curie Research infrastructures LEIT Leadership in enabling and Industrial Technologies ICT Nanotechnologies Advanced materials Biotechnology Advanced manufacturing and processing Space Access to risk finance Innovation in SMEs Health, demographic change and wellbeing Food security, sustainable agriculture and forestry, water research and bioeconomy Secure, clean and efficient energy Smart, green and integrated transport Climate action, environment, ressource efficiency, raw materials Europe in a changing world - inclusive, innovative and reflective societies Secure Societies - freedom and security of Europe and its citizens Stuttgart, 04. April

8 Excellent Science Aims: Part I Excellent Science European Research Council - ERC Future & emerging Technologies - FET Marie-Skłodowska- Curie Research infrastructures» To strengthen and widen excellence of science basis» Consolidation of the European research area» Increase global competitiveness of the EU research and innovation systems Trends: Research-driven approaches bottom-up Science as the driver Stuttgart, 04. April

9 Industrial Leadership II. Industrial Leadership LEIT Leadership in enabling and Industrial Technologies ICT Nanotechnologies Advanced materials Biotechnology Advanced manufacturing and processing Space Access to risk finance Innovation in SMEs Aims: Boost the development of technologies and innovations Key Enabling Technologies (KET) Build foundation for tomorrow s companies Support to innovative European SMEs Trends: Strategic Agendas of industry define the calls Close-to-market activities industry in driver seat Stuttgart, 04. April

10 Industrial Leadership II. Industrial Leadership LEIT Leadership in enabling and Industrial Technologies ICT Nanotechnologies Advanced materials Biotechnology Advanced manufacturing and processing Space Access to risk finance Innovation in SMEs Aims: Boost the development of technologies and innovations Key Enabling Technologies (KET) Build foundation for tomorrow s companies Support to innovative European SMEs Trends: Strategic Agendas of industry define the calls Close-to-market activities industry in driver seat Stuttgart, 04. April

11 Innovation in SMEs II. Industrial Leadership LEIT Leadership in enabling and Industrial Technologies ICT Nanotechnologies Advanced materials Biotechnology Advanced manufacturing and processing Space Aim: close the gap for early phases of high risk research and innovation Broad meaning of innovation: technological and non-technological, social and service innovation (European added-value) Bottom-up approach Easy Access through simple rules and procedures Implementation: different measures, e.g. SME instrument Access to risk finance Innovation in SMEs Stuttgart, 04. April

12 Societal Challenges III. Societal Challenges Health, demographic change and wellbeing Food security, sustainable agriculture and forestry, water research and bioeconomy Secure, clean and efficient energy Smart, green and integrated transport Climate action, environment, ressource efficiency, raw materials Europe in a changing world - inclusive, innovative and reflective societies Secure Societies - freedom and security of Europe and its citizens Aims: Support the political goals as defined in the Europe 2020 Strategy Cover the whole cycle from research and innovation to the market Needs critical mass, interdisciplinarity Trends: Focus on 7 priority areas Support of the whole innovation chain: research, technological development, demonstration and innovation activities Stuttgart, 04. April

13 Societal Challenge 1: Health, demographic change and wellbeing III. Societal Challenges Health, demographic change and wellbeing Food security, sustainable agriculture and forestry, water research and bioeconomy Secure, clean and efficient energy Smart, green and integrated transport Climate action, environment, ressource efficiency, raw materials Europe in a changing world - inclusive, innovative and reflective societies Secure Societies - freedom and security of Europe and its citizens Challenges: Increasing costs for health care systems due to ageing population Requires effective prevention, treatment and management of disease and disability Focus: chronic diseases, infectious disease Aims: Improve life long health and wellbeing High quality, sustainable health care systems Improve growth and employment Stuttgart, 04. April

14 Societal Challenge 1: Health Demographic Change and Wellbeing Joint work of DG RTD (Research and Innovation) and DG CNECT (Communications Networks, Content & Technology) ehealth integrated Not structured along diseases broad topics Structured into 7 chapters covering the whole range of health research: 1.1. Understanding health, wellbeing and disease 1.2. Preventing disease 1.3. Treating and managing disease 1.4. Active ageing and self-management of health 1.5. Methods and data 1.6. Health care provision and integrated care 1.7. Specific implementation aspects Stuttgart, 04. April

15 Implementation of Societal Challenge 1 Commission Funding through H2020 Public Private Partnership(s) PPPs Funding through H industry IMI Innovative Medicines Initiative (IMI2) Public-Public Partnerships - P2Ps Funding through Member States + partly H2020 JPIs MS JPND-neuro-deg., MYBL-demogr. change, JPAMR-resistence, JP-AHDL-nutrition and health ERA-Nets MS (+ COM) neuro-degenerative diseases, brain, HIV/AIDS, cancer, rare diseases, CVD, systems medicine, AM Art. 185 actions (MS + COM) EDCTP2 (Infections Africa), AAL2 (assisted living) Stuttgart, 04. April

16 Innovative Medicines Initiative (IMI) Largest Public-Private Partnership in the area of biomedicine Innovative cooperation between European Commission and EFPIA (European Federation of Pharmaceutical Industries and Associations) Aims to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. to strengthen medical innovation potential in Europe. to decrease shortages in drug development. Contact person in NKS-L Jan Skriwanek: Tel Characteristics EU funding exclusively to academia, SME, patient organisations and regulatory authorities; EFPIA companies participates through in kind contributions Stuttgart, 04. April

17 IMI 2 - Call 8 Topic: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks for the entire period of 2 years is a maximum of EUR IMI 2 - Future Topics Topics: Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer s disease Fairification (Findable, Accessible, Interoperable, Reusable) of IMI and EFPIA data Development of sensitive and validated clinical endpoints in primary Sjögren s syndrome European screening centre: unique library for attractive biology Exploitation of IMI project results Stuttgart, 04. April

18 Important European Initiatives - Health Public Private Partnerships (Kommission + Industrie), JTI nach Art. 187 IMI2 pharma, imaging, diagnostics, HTA, etc. Public Public Partnerships (Kommission + MS) nach Art. 185 EDCTP clinical trials in Sub-Sahara Africa, PRD, NID Active Assisted Living 2 assistance systems, ehealth, IKT Public Public Partnerships (MS + z.t. Kommission) Joint Programming und ERA-Nets JPND Neuro-degenerative diseases JPI-AMR antimicrobial resistence JPI-HDHL (SC2) nutrition & health JPI-MYBL demographic change ERA-Net Neuron neurological diseases ERA-Net E-Rare rare diseases ERA-Net TRANSCAN Translational cancer research ERA-Net ERACoSysMed Systems medicine e ERA-Net EuroNanoMed (NMBP) Nanomedicin e(ket NMBP) ERA-Net CVD Cardiovascular diseases IC PerMed In Vorbereitung Personalised medicine Knowledge and Innovation Community (KIC) des European Institute of Innovation and Technology (EIT) EIT health Demograph. Change, health economics European Innovation Partnerships - EIPs AHA, Active and healthy ageing Demographic change Stuttgart, 04. April

19 Eligible for funding in H2020 Treated equally 28 EU member states (MS) Associated / candidate states (AS): AL, AM, BA, CH, FO, GE, IL, IS, MD, ME, MK, NO, RS, TN, TR, UA Third countries High-income countries incl. BRIC + Mexico Only exceptionally* or when mentioned in WP Third countries with low or medium income (listed in Annex A of WP) * Exception in SC 1: institutions from the US are eligible for funding Stuttgart, 04. April

20 Rules of Participation minimum number of partners In general: at least 3 independent legal entities from 3 different EU Member States (MS) or associated states (AS) 3 Exception: ERC Marie Skłodowska-Curie Actions SME instrument CSA Explicitely mentioned in work programme 1 Stuttgart, 04. April

21 Outlook next Working programme Call 1. "Better Health and care, economic growth and sustainable health systems (DG RTD) Priority 1.1 Personalised medicine Priority 1.2 Innovative health and care industry Priority 1.3 Infectious diseases and improving global health Priority 1.4 Innovative health and care systems - Integration of care Priority 1.5 Decoding the role of the overall environment for health and well-being Call 2. "Digital transformation in Health and Care" (DG CNECT) Call 3. "Trusted digital solutions and Cybersecurity in Health and Care" Attention - preliminary information! Stuttgart, 04. April

22 SC1 Topics WP Call 1. "Better Health and care, economic growth and sustainable health systems Priority 1.1 Personalised medicine Instrume nt Single or 2- Stage Budget / proposal / total deadline SC1-BHC : International flagship collaboration with Canada for human data storage, integration and sharing for developing personalised medicine approaches RIA single stage 6 Mio over 4 years / 40 Mio SC1-BHC : Digital diagnostics developing tools for clinical decisions integrating in vitro & in vivo diagnostics RIA 2 stage SC1-HCO : Data integration and data-driven in-silico models for enabling personalised medicine - a European standardization framework CSA single-stage 1,5-2 Mio / 2 Mio Priority 1.2 Innovative health and care industry Instrum ent Single or 2- Stage Budget / proposal / total deadline SC1-BHC : Regenerative medicine: from new insights to new applications RIA Single stage 6-8 Mio / 50 Mio SC1-BHC : New therapies for Non Communicable Diseases RIA 2-stage SC1-BHC : Innovation platforms for advanced therapies of the future RIA Single stage Mio / 50 Mio SC1-BHC : Boosting the translation of results of health research into validated, innovative applications RIA/IA 2 stage Attention - preliminary information! Stuttgart, 04. April

23 SC1 Topics WP Call 2. "Digital transformation in Health and Care Instrume nt Single or 2- Stage Budget / proposal / total deadline SC1-DTH : Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment SC1-DTH : International cooperation in digital solutions and robotics for independent living SC1-DTH : Accelerating the uptake of in-silico methods for testing medicines with dermatological use and cosmetic products SC1-DTH : Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments SC1-DTH : Piloting a cloud-based standardised Personal Health Record/Electronic Health Record for Europe SC1-HCC : Support to further development of international cooperation in digital transformation of health and care SC1-HCC : ehealth and care services support for policy, strategy and post R&D RIA single stage 3-5 Mio / 25 Mio spring 2019 RIA Single stage IA single stage RIA single stage Mio / 40 Mio spring 2018 RIA single stage x / 20 Mio spring 2018 CSA single-stage x / 2 Mio spring 2018 CSA single-stage 3 Mio / 3 Mio spring 2018 SC1-HCC : Support to ehealth Innovation ecosystems in Europe CSA single-stage Attention - preliminary information! Stuttgart, 04. April

24 SC1 Topics WP Call 3. "Trusted digital solutions and Cybersecurity in Health and Care Instrume nt Single or 2- Stage Budget / proposal / total deadline DT : Smart and healthy living at home - topic only for 2019 IA Single stage Mio / 35 Mio spring 2019 SU-TDS : Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect data/infrastructures - topic only for 2018 SU-TDS : Raising awareness and developing training schemes on cybersecurity in hospitals - topic only for 2018 RIA Single stage x / 35 Mio spring 2018 CSA single-stage 1 Mio spring 2018 No information on upcoming Biotec Topics yet Attention - preliminary information! Stuttgart, 04. April

25 Where to find calls and documents pants/portal/desktop/en/home.html Overview of currently open health calls Stuttgart, 04. April

26 Major dates of important events Info Days of the European Commission Open Info Day Challenge SC1 (Health): 8 Dec 2017 in Brussels Brokerage events Challenge SC1 (Health): 8 Dec 2017 in Brussels Biotec/Bioeconomy: Nov 2017 in Brussels Stuttgart, 04. April

27 Read your colleagues proposals Register as an expert or make sure that your profile is up to date Stuttgart, 04. April

28 National Contact Points Services offered - free of charge Does your idea fit into Horizon 2020 Scanning programmes and initiatives to find suitable funding possibilities Individual consultancy: proposal planning / proposal preparation / project management Critical review of proposal outlines/drafts and full proposals Workshops Proposal Writing Partnering activities: Guidelines and supporting documents: Workshops or Webinars Newsletter: alert service for calls, important european developments and events Internet Stuttgart, 04. April

29 NCP System - 22 National Contact Points in DE National NCP Coordinator Legal and Financial aspects SMEs* Access to Finance* * In liaison with EEN European Research Council Future and Emerging Technologies Marie Skłodowska-Curie actions on skills, training and career development European research infrastructures Information and Communication Technologies (ICT) Nanotechnologies, advanced materials and advanced manufacturing and processing Space Health, demographic change and wellbeing Food security, sustainable agriculture, marine and maritime research and the bio-economy & Biotechnology Secure, clean and efficient energy Smart, green and integrated transport Climate action, resource efficiency and raw materials Inclusive, innovative, reflective societies Security Widening Participation Science with and for Society Euratom Joint Research Center (JRC) Stuttgart, 04. April

30 NCP System - 22 National Contact Points in DE National NCP Coordinator Legal and Financial aspects SMEs* Access to Finance* * In liaison with EEN European Research Council Future and Emerging Technologies Marie Skłodowska-Curie actions on skills, training and career development European research infrastructures Information and Communication Technologies (ICT) Nanotechnologies, advanced materials and advanced manufacturing and processing Space Health, demographic change and wellbeing Food security, sustainable agriculture, marine and maritime research and the bio-economy & Biotechnology Secure, clean and efficient energy Smart, green and integrated transport Climate action, resource efficiency and raw materials Inclusive, innovative, reflective societies Security Widening Participation Science with and for Society Euratom Joint Research Center (JRC) Stuttgart, 04. April

31 National Contact Points Networks & supporting projects Health Biotec Call Calender, News & Events, Brokerage Events, Webinars Services for Health SMEs, SC1 Partnering Tool, Webinars News & Events, Brokerage Events, Webinars Stuttgart, 04. April

32 Thank you for your attention! Dr. Lydia Kammler National Contact Point for Health DLR project management agency (DLR Projektträger) Heinrich-Konen-Str Bonn Tel Fax lydia.kammler@dlr.de Stuttgart, 04. April